TBP — Tetra Bio Pharma Share Price
0.000.00%
Last trade - 00:00HealthcareSpeculativeMicro Cap
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | -315.85% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 30th Nov | Unit | 2017 | 2018 | 2019 | 2020 | 2021 | 2022E | 2023E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | CA$m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Tetra Bio-Pharma Inc. is a Canada-based cannabinoid-derived drug discovery and development company. The Company has developed a pipeline of cannabinoid-based drug products for a range of medical conditions, including pain, inflammation, and oncology. The Company has a pipeline of formulations and drug delivery systems with a portfolio of assets in early research and development phase to advanced stage clinical programs. Its products include QIXLEEF, CAUMZ, PPP004, REDUVO, and REBORN 1. QIXLEEF is a botanical therapy with a fixed dosage of tetrahydrocannabinol (THC) and cannabidiol (CBD). CAUMZ is its inhaled cannabinoid-derived drug candidate. PPP004 is a topical preparation containing either a standardized amount of CBD or a defined ratio of THC and CBD. REDUVO is a soft gel capsule used to treat chemotherapy-induced nausea and vomiting (CINV) and weight loss and severe nausea in people living with human immunodeficiency virus (HIV) infection. REBORN 1 is in phase II study.
Directors
- William Cheliak NEC
- Guy Chamberland CEO
- Jean-Francois Boily CFO
- Graham Wood COO
- Dania Scott SVP
- Melanie Kelly CSO
- Steve Neron OTH
- Carl Merton IND
- Brent Norton IND (59)
- Dale Weil IND (65)
- Last Annual
- November 30th, 2021
- Last Interim
- August 31st, 2022
- Incorporated
- May 17th, 2007
- Public Since
- April 15th, 2008
- No. of Employees
- 33
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Toronto Stock Exchange
- Shares in Issue
- 515,634,205
- Address
- 2316 St-Joseph Blvd., ORLEANS, K1C 1E8
- Web
- https://tetrabiopharma.com/
- Phone
- +1 3436890714
- Contact
- Natalie Leroux
- Auditors
- UHY McGovern Hurley LLP
Upcoming Events for TBP
Similar to TBP
Aurora Cannabis
Toronto Stock Exchange
Auxly Cannabis
Toronto Stock Exchange
Bausch Health Companies
Toronto Stock Exchange
Canopy Growth
Toronto Stock Exchange
Charlotte's Web Holdings
Toronto Stock Exchange
FAQ
What is the Tetra Bio Pharma share price?
As of Today at 07:23 UTC, shares in Tetra Bio Pharma are trading at CA$0.03. This share price information is delayed by 15 minutes.
How has the Tetra Bio Pharma share price performed this year?
Shares in Tetra Bio Pharma last closed at CA$0.03 and the price had moved by -64.29% over the past 365 days. In terms of relative price strength the Tetra Bio Pharma share price has underperformed the Toronto Stock Exchange 300 Composite Index by -67.03% over the past year.
What are the analyst and broker recommendations for Tetra Bio Pharma?
The overall consensus recommendation for Tetra Bio Pharma is Strong Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Tetra Bio Pharma dividend yield?
Tetra Bio Pharma does not currently pay a dividend.
Does Tetra Bio Pharma pay a dividend?
Tetra Bio Pharma does not currently pay a dividend.
When does Tetra Bio Pharma next pay dividends?
Tetra Bio Pharma does not currently pay a dividend.
How do I buy Tetra Bio Pharma shares?
To buy shares in Tetra Bio Pharma you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Tetra Bio Pharma?
As of the previous close price of CA$0.03, shares in Tetra Bio Pharma had a market capitalisation of .
Where are Tetra Bio Pharma shares listed?
Here are the trading details for Tetra Bio Pharma:
- Country of listing: Canada
- Exchange: TOR
- Ticker Symbol: TBP
What kind of share is Tetra Bio Pharma?
Based on an overall assessment of its quality, value and momentum Tetra Bio Pharma is currently classified as a . The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Tetra Bio Pharma share price forecast for 2023?
We could not find analyst target price data for this security.
What is the trend in the Tetra Bio Pharma share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Tetra Bio Pharma. Over the past six months, its share price has underperformed the Toronto Stock Exchange 300 Composite Index by -58%.
As of the last closing price of CA$0.03, shares in Tetra Bio Pharma were trading matched their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Tetra Bio Pharma PE Ratio?
The Tetra Bio Pharma PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at CA$0.03.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Tetra Bio Pharma?
Tetra Bio Pharma's management team is headed by:
- William Cheliak - NEC
- Guy Chamberland - CEO
- Jean-Francois Boily - CFO
- Graham Wood - COO
- Dania Scott - SVP
- Melanie Kelly - CSO
- Steve Neron - OTH
- Carl Merton - IND
- Brent Norton - IND
- Dale Weil - IND